Posted by Michael Wonder on 07 Mar 2023
Ionis announces FDA acceptance of new drug application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
7 March 2023 - FDA assigns PDUFA action date of 22 December 2023.
Ionis Pharmaceuticals today announced that the US FDA has accepted for review a new drug application for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy.
